vTv Therapeutics (FRA:5VT0) Piotroski F-Score: 5 (As of Jun. 26, 2026) — 67% Above Median


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €30.80
GF Value €6,491.15
! 1 Warning Sign
View Full Analysis

What is vTv Therapeutics Piotroski F-Score?

vTv Therapeutics FRA:5VT0 +1.32% 35 Piotroski F-Score is 5 as of Jun. 26, 2026, which is 67% above its 10-year median of 3.00. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,491.15. The stock has 1 warning sign investors should review. Among 1,342 Biotechnology companies, vTv Therapeutics ranks better than 85.1% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

vTv Therapeutics has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for vTv Therapeutics's Piotroski F-Score or its related term are showing as below:

FRA:5VT0' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 5

During the past 13 years, the highest Piotroski F-Score of vTv Therapeutics was 5. The lowest was 1. And the median was 3.

vTv Therapeutics  (FRA:5VT0) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


vTv Therapeutics Piotroski F-Score Related Terms


vTv Therapeutics Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics Piotroski F-Score Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 4.00 3.00 4.00

vTv Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 4.00 4.00 5.00

FRA:5VT0 vs CRDF, GUTS, ACOG: Piotroski F-Score Comparison

For the Biotechnology subindustry, vTv Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Piotroski F-Score falls into.


FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -5.242 + -7.411 + -6.096 + 20.876 = €2.13 Mil.
Cash Flow from Operations was -4.417 + -4.449 + -7.9 + 7.918 = €-8.85 Mil.
Revenue was 0 + 0 + 0 + 31.866 = €31.87 Mil.
Gross Profit was 0 + 0 + 0 + 31.866 = €31.87 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(29.625 + 22.93 + 84.769 + 76.774 + 85.473) / 5 = €59.9142 Mil.
Total Assets at the begining of this year (Mar25) was €29.63 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €85.47 Mil.
Total Current Liabilities was €5.95 Mil.
Net Income was -4.812 + -4.309 + -3.47 + -4.71 = €-17.30 Mil.

Revenue was 0 + 0 + 0.016 + 0 = €0.02 Mil.
Gross Profit was 0 + 0 + 0.016 + 0 = €0.02 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(49.848 + 43.159 + 38.891 + 36.544 + 29.625) / 5 = €39.6134 Mil.
Total Assets at the begining of last year (Mar24) was €49.85 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €29.52 Mil.
Total Current Liabilities was €3.99 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

vTv Therapeutics's current Net Income (TTM) was 2.13. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

vTv Therapeutics's current Cash Flow from Operations (TTM) was -8.85. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=2.127/29.625
=0.07179747

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-17.301/49.848
=-0.34707511

vTv Therapeutics's return on assets of this year was 0.07179747. vTv Therapeutics's return on assets of last year was -0.34707511. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

vTv Therapeutics's current Net Income (TTM) was 2.13. vTv Therapeutics's current Cash Flow from Operations (TTM) was -8.85. ==> -8.85 <= 2.13 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/59.9142
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/39.6134
=0

vTv Therapeutics's gearing of this year was 0. vTv Therapeutics's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=85.469/5.952
=14.35971102

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=29.522/3.992
=7.39529058

vTv Therapeutics's current ratio of this year was 14.35971102. vTv Therapeutics's current ratio of last year was 7.39529058. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

vTv Therapeutics's number of shares in issue this year was 14.634. vTv Therapeutics's number of shares in issue last year was 6.583. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=31.866/31.866
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.016/0.016
=1

vTv Therapeutics's gross margin of this year was 1. vTv Therapeutics's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=31.866/29.625
=1.07564557

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0.016/49.848
=0.00032098

vTv Therapeutics's asset turnover of this year was 1.07564557. vTv Therapeutics's asset turnover of last year was 0.00032098. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

vTv Therapeutics has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
vTv Therapeutics (FRA:5VT0) has a Piotroski F-Score of 5 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on vTv Therapeutics and its competitors. This is 67% above median its historical median of 3.00. Over the past decade, vTv Therapeutics' Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, vTv Therapeutics ranks #200 out of 1342 companies in the Biotechnology industry, placing it in the top 14.9%.
Is vTv Therapeutics' Piotroski F-Score too high?
vTv Therapeutics' current Piotroski F-Score of 5 is 67% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. vTv Therapeutics' value of 5 is 66.7% above this industry median. Based on the distribution chart, vTv Therapeutics ranks #200 out of 1342 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Piotroski F-Score compare to CRDF and GUTS?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #200 out of 1342 companies for Piotroski F-Score. This places vTv Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. vTv Therapeutics' value of 5 is 66.7% above this benchmark. Historically, vTv Therapeutics' own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, vTv Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. vTv Therapeutics's current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on vTv Therapeutics and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. vTv Therapeutics's current Piotroski F-Score is 5, which is 67% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Piotroski F-Score of 5. The stock's GF Value™ is €6,491.15, compared to a current price of €30.80 — trading 99.5% below its estimated fair value. The current Piotroski F-Score is 5, which is 67% above median its 10-year median of 3.00 and 66.7% above the Biotechnology industry median of 3.00. vTv Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Piotroski F-Score is 5 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €30.80 is trading 99.5% below its estimated GF Value™ of €6,491.15.

Key valuation signals for FRA:5VT0:

  • Piotroski F-Score: 5 (67% above median its 10-year median of 3.00)
  • GF Value™: €6,491.15 vs. price of €30.80 (99.5% below fair value)
  • GF Score™: 35/100 with 1 warning sign
  • Industry Position: 66.7% above the Biotechnology median (#200 of 1342)

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.80
Price
€6,491.15
GF Value